Cannabinoids: research and patient questions (Page 3)

It helped: The new powder form led to higher levels of cannabinoids in the blood and reached those peaks much faster than standard oil drops, while both versions were well tolerated.

Consider the use of oral cannabinoids as a potential treatment option for patients with insomnia, while monitoring for individual responses and side effects.

Clinicians should consider the potential benefits of cannabinoids for improving sleep in patients with chronic neuropathic pain, while remaining cautious about the limited evidence for pain relief.

Clinicians should consider the use of cannabis and cannabinoids as part of a comprehensive treatment plan for cancer patients, focusing on symptom management and patient quality of life.

Clinicians should be cautious when prescribing cannabinoid-based medicines to older adults due to the limited data on adverse events. Monitoring for potential adverse effects is essential.

This systematic review and meta-analysis demonstrates that standard personality traits do not reliably predict placebo responsiveness, challenging the clinical assumption of a 'placebo personality'. Clinicians and researchers should look to situational, contextual, learning-based, or neurobiological factors rather than baseline personality when assessing variability in patient response to inert treatments or therapies.

The study highlights the importance of understanding the relationship between gene and protein expression for the CB1 receptor, which may inform future drug development strategies.

While cannabinoids may offer targeted relief for specific PTSD symptoms like nightmares and sleep disturbances (Cluster B and E), current evidence does not support major global improvements in overall PTSD severity. Furthermore, frequent use or concurrent Cannabis Use Disorder (CUD) is strongly linked to worsening symptom trajectories, increased suicidality, and aggressive behaviors, necessitating careful screening and caution in clinical practice.

While observational studies and one RCT suggest modest behavioral and social communication benefits from full-spectrum, high-CBD-to-THC cannabis extracts in pediatric autism spectrum disorder, current robust trial data do not support generalized routine use. Cannabinoids should be reserved as an adjunctive therapeutic option under strict specialist medical supervision, carefully weighing the modest potential benefits against the neurodevelopmental and cognitive risks of pediatric THC exposure.